G A Cline

Summary

Affiliation: The Procter and Gamble Company
Country: USA

Publications

  1. pmc Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study
    Jean Pierre Pelletier
    Osteoarthritis Research Unit, University of Montreal Hospital Center, 1560 Sherbrooke Street East, Montreal, QC, Canada H2L 4M1
    Arthritis Res Ther 9:R74. 2007
  2. pmc Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
    Tim D Spector
    Twin Research and Genetic Epidemiology Unit, St Thomas Hospital, London, UK
    Arthritis Res Ther 7:R625-33. 2005
  3. pmc Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study
    Piotr Krzeski
    Procter and Gamble Pharmaceuticals, Whitehall Lane, Egham TW20 9NW, Surrey, UK
    Arthritis Res Ther 9:R109. 2007
  4. pmc Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes
    Jean Pierre Raynauld
    Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre Dame Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, Canada
    Arthritis Res Ther 8:R21. 2006
  5. ncbi request reprint Comparison of fixed flexion, fluoroscopic semi-flexed and MTP radiographic methods for obtaining the minimum medial joint space width of the knee in longitudinal osteoarthritis trials
    G A Cline
    Procter and Gamble Pharmaceuticals, Mason, OH 45040, USA
    Osteoarthritis Cartilage 14:A32-6. 2006
  6. pmc Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging
    M J Berthiaume
    Centre Hospitalier de l Universite de Montreal, Department of Radiology, Notre Dame Hospital, Quebec, Canada
    Ann Rheum Dis 64:556-63. 2005
  7. ncbi request reprint Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period
    J P Raynauld
    Osteoarthritis Research Unit, University of Montreal Hospital Centre CHUM, Notre Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec, Canada
    Ann Rheum Dis 67:683-8. 2008
  8. ncbi request reprint Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
    P Garnero
    INSERM Research Unit 664, Lyon, France
    Osteoarthritis Cartilage 16:660-6. 2008

Collaborators

Detail Information

Publications8

  1. pmc Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study
    Jean Pierre Pelletier
    Osteoarthritis Research Unit, University of Montreal Hospital Center, 1560 Sherbrooke Street East, Montreal, QC, Canada H2L 4M1
    Arthritis Res Ther 9:R74. 2007
    ..This study also further confirms the correlation between cartilage volume loss and JSN and symptomatic changes at 24 months...
  2. pmc Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]
    Tim D Spector
    Twin Research and Genetic Epidemiology Unit, St Thomas Hospital, London, UK
    Arthritis Res Ther 7:R625-33. 2005
    ..Both doses of risedronate were well tolerated. In this study, clear trends towards improvement were observed in both joint structure and symptoms in patients with primary knee OA treated with risedronate...
  3. pmc Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study
    Piotr Krzeski
    Procter and Gamble Pharmaceuticals, Whitehall Lane, Egham TW20 9NW, Surrey, UK
    Arthritis Res Ther 9:R109. 2007
    ..This study adds to the weight of evidence suggesting that side effect profiles of MMP inhibitors in general make them unsuitable for use in osteoarthritis...
  4. pmc Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes
    Jean Pierre Raynauld
    Osteoarthritis Research Unit, University of Montreal Hospital Centre, Notre Dame Hospital, Department of Medicine, University of Montreal, Montreal, Quebec, Canada
    Arthritis Res Ther 8:R21. 2006
    ..These data confirm the significant advantage of qMRI for reliably measuring knee structural changes at as early as 12 months, and for identifying risk factors associated with OA progression...
  5. ncbi request reprint Comparison of fixed flexion, fluoroscopic semi-flexed and MTP radiographic methods for obtaining the minimum medial joint space width of the knee in longitudinal osteoarthritis trials
    G A Cline
    Procter and Gamble Pharmaceuticals, Mason, OH 45040, USA
    Osteoarthritis Cartilage 14:A32-6. 2006
    ....
  6. pmc Meniscal tear and extrusion are strongly associated with progression of symptomatic knee osteoarthritis as assessed by quantitative magnetic resonance imaging
    M J Berthiaume
    Centre Hospitalier de l Universite de Montreal, Department of Radiology, Notre Dame Hospital, Quebec, Canada
    Ann Rheum Dis 64:556-63. 2005
    ..The relation between knee meniscal structural damage and cartilage degradation is plausible but not yet clearly proven...
  7. ncbi request reprint Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period
    J P Raynauld
    Osteoarthritis Research Unit, University of Montreal Hospital Centre CHUM, Notre Dame Hospital, 1560 Sherbrooke Street East, Montreal, Quebec, Canada
    Ann Rheum Dis 67:683-8. 2008
    ..To evaluate in patients with knee osteoarthritis (OA) the size changes in bone oedema and cysts over 24 months, and to contrast these changes with cartilage volume loss using quantitative magnetic resonance imaging...
  8. ncbi request reprint Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial
    P Garnero
    INSERM Research Unit 664, Lyon, France
    Osteoarthritis Cartilage 16:660-6. 2008
    ....